Top
Potential sale of French operations/trading update

RNS Number : 3978D
Polypipe Group PLC
31 January 2018
 

31 January 2018

Polypipe Group plc

 Exclusive negotiations for the sale of French operations and trading update

 

Exclusive negotiations for the sale of French operations

Polypipe Group plc ("Polypipe" or the "Company") has entered into exclusive negotiations to sell Polypipe France Holding ("Polypipe France"), its French operations, to Ryb S.A. ("Ryb"), a France-based manufacturer and distributor of plastics in Europe (the "Disposal"). The cash consideration payable by Ryb will be €16.5 million on a debt free, cash-free and normalised working capital basis.

For the year ended 31 December 2017, Polypipe France generated revenue of approximately €67.6m and underlying operating profit of approximately €1.5m.

Completion of the transaction, which remains subject to an employee consultation process, is expected in the first half of 2018. Proceeds from the Disposal, receivable in cash at completion, will be used to reinvest in the growth of the Company.

Trading update

Further to the update on trading announced in November 2017, the Group's trading performance for the full year was in line with management expectations. The Company will announce its preliminary results on 20 March 2018.

Commenting on the transaction, Martin Payne, Chief Executive Officer, said:

"Polypipe France has historically operated in a competitive area of the French construction market and will be better able to grow under new ownership. In line with its strategy, Polypipe will continue to focus its resources fully on delivering profitable growth, both organically and by acquisition, through legacy material substitution, legislative tailwinds in water management and carbon reduction, and geographic reach." 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) No 596/2014.

Enquiries:

Polypipe                                                                                              

Martin Payne, Chief Executive Officer                                          +44 (0) 1709 770 000

                                               

Brunswick                                                                                           

Nina Coad                                                                                           +44 (0) 2074 045 959

Elena Georgantzi

                                                                    

 

Notes to Editors:

Polypipe is the largest manufacturer in the UK, and among the ten largest manufacturers in Europe, of plastic piping systems for the residential, commercial, civils and infrastructure sectors by revenue.  It is also a leading designer and manufacturer of energy efficient ventilation systems in the UK.

The Group operates from 20 facilities in total, and with over 20,000 product lines, manufactures the UK's widest range of plastic piping systems for heating, plumbing, drainage and ventilation. The Group primarily targets the UK and European building and construction markets with a presence in Italy and the Middle East and sales to specific niches in the rest of the world.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDBRGDBRUXBGIG

COVID 19 update

RNS Number : 6007H
Polypipe Group PLC
25 March 2020
 

25 March 2020

 

Polypipe Group plc

 

COVID 19 update

 

Polypipe Group plc ("Polypipe", the "Company" or the "Group"), a leading provider of sustainable water and climate management solutions for the built environment, today provides the following COVID 19 update.

Employees, customers and operations

The health, safety and wellbeing of our people has always been, and continues to be, at the forefront of everything we do. The Group and its leadership team has a duty of care to its employees and customers, and the evaluation of risk and taking mitigating actions to protect those employees and customers is taken very seriously and is very much ingrained in our culture. In light of recent events and until further notice, we have decided to wind down our operations to that which is absolutely necessary to support the Government in its battle with COVID 19 and keep the economy going. These include the following:

·     Parts of the Group supporting the National Health Service in very specific roles in increasing capabilities to cope with the inevitable increase in COVID 19 patients. Our Nuaire business is manufacturing ventilation for the Royal Marsden Hospital and is receiving urgent enquiries from many other NHS sites for this as well as other essential projects.

·     Our Building Products business has been requested to manufacture special pipe for emergency medical use.

·     On a wider front, it is necessary to keep supplying some of our plumbing and drainage products that are needed for urgent repair and maintenance across the country to keep essential projects and services running.

The reduction in our operations will happen over the next few days as, for operational reasons, it is not something that can be done immediately. 

Current trading and FY20 guidance

Trading for the year to date has been in line with expectations, with no material impact on performance from the COVID 19 pandemic so far. However, the decision to wind down operations, and the inevitable but as yet unquantifiable wider impact of COVID 19 on our end markets in the next weeks and months means it is no longer possible to provide financial guidance for the year ending 31 December 2020 and beyond. Guidance will be resumed when a degree of normality returns to our markets.

Focus on cash preservation and withdrawal of FY19 final dividend

It is clear that both revenues and profits will be adversely impacted in the coming months by the decision to wind down operations and by the effect of COVID 19 on our end markets. In response, we have implemented a range of measures to reduce costs and conserve cash during this period, including utilisation of the Job Retention Scheme and other measures announced by the Government.

Whilst the Board recognises the importance of the dividend to shareholders, as part of its cash conservation plans, the Board has decided to withdraw its recommendation to pay a final dividend of 8.1 pence per share on 28 May 2020, and this will not now be put to shareholders at the AGM on 21 May 2020. This decision will ensure £16m cash will be retained in the business that would otherwise have been distributed which the Board believes is prudent and appropriate in the current circumstances.

The Group enters this period of uncertainty with a strong balance sheet and good liquidity. Excluding IFRS16, net debt at 31 December 2019 stood at £150.0m, representing 1.5 times EBITDA on a pre IFRS16 basis. The Group has a £300m Revolving Credit Facility, committed through to November 2023, and has taken pre-emptive action in drawing down all but £15m of the unutilised facility and holds it on deposit across several banks.

Commenting on this announcement, Martin Payne, Chief Executive Officer, said "In these unprecedented times we have acted swiftly and decisively, taking our decisions with the best interests of our employees and customers foremost in our minds. The Board's thoughts are with all of our employees and their families in what are worrying times for us all. The Group's strong balance sheet and cash generation, together with our talented people and clear strategy gives the Board confidence that it will overcome whatever challenges await."

 

Enquiries:

 

Polypipe

Martin Payne, Chief Executive Officer

Paul James, Chief Financial Officer

 

+44 (0) 1709 770 000

Brunswick

Nina Coad

Dan Roberts

Sophia Lazarus

 

+44 (0) 20 7404 5959

Notes to Editors:

Polypipe Group plc ("Polypipe", the "Company" or the "Group"), a leading provider of sustainable water and climate management solutions for the built environment is the largest manufacturer in the UK, and among the ten largest manufacturers in Europe, of plastic piping systems for the residential, commercial, civils and infrastructure sectors by revenue.  It is also a leading designer and manufacturer of energy efficient ventilation systems in the UK.

The Group operates from 19 facilities in total, and with over 20,000 product lines, manufactures the UK's widest range of plastic piping systems for heating, plumbing, drainage and ventilation. The Group primarily targets the UK and European building and construction markets with a presence in Italy, the Netherlands, Ireland and the Middle East and sales to specific niches in the rest of the world.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUVOSRRKUOUAR

COVID-19 Update

RNS Number : 1974M
Polypipe Group PLC
07 May 2020
 

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

 

FURTHER THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE SEE THE CAUTIONARY STATEMENT AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

For immediate release

 

7 May 2020

 

Polypipe Group plc

COVID-19 update

 

Polypipe Group plc ("Polypipe", the "Company" or the "Group"), a leading provider of sustainable water and climate management solutions for the built environment, today provides an update following its announcement on 25 March 2020 on the impact of the COVID-19 pandemic, and the Group's response to date.

 

Current operations

We continue to prioritise the health, safety and wellbeing of our employees, adhering to government guidelines on social distancing and hygiene in all aspects of our operations.

The Group has been operating at approximately 70% below normal demand, supplied mainly from existing stock, driven by urgent NHS and care-related activity as well as some ongoing infrastructure and commercial work, and essential Repair, Maintenance, and Improvement ("RMI").

Management actions

As previously announced, in response to COVID-19, the Company has implemented a range of measures to reduce costs and conserve cash during this period. These actions include:

·     furloughing approximately 60% of our workforce and keeping this under constant review as circumstances change;

·     severely curtailing capital expenditure, which was expected to have been approximately £25 million for the FY20 financial year;

·     standing down all agency staff and any consultants;

·     curtailing discretionary spend whilst honouring contractual payment terms with creditors;

·     negotiating temporary lease terms with some providers and agreeing return to normal (non-early) payment terms with some suppliers;

·     cancelling the FY19 final dividend which was due for payment on 28 May 2020, saving the Group £16 million of cash;

·     reductions in base salary/fees for both executive directors and non-executive directors of 20% until further notice;

·     agreeing with HMRC that PAYE and NIC payments that are due will be deferred until June 2020 and VAT payments deferred until March 2021; and

·     as set out in detail below, taking a number of steps to increase the Group's banking facilities and liquidity and also securing agreement from our banking group to temporarily waive certain requirements within the Group's Revolving Credit Facility Agreement (the "RCF") as a result of the impact of COVID-19 on the business and operations of the Group and to suspend the June 2020 quarterly leverage covenant test.

 

Financing, cash management and covenant waiver

The Group entered this period of uncertainty with a strong balance sheet and good liquidity. Excluding IFRS16, net debt at 31 December 2019 stood at £150.0 million, representing 1.5 times EBITDA on a pre IFRS16 basis. Net debt as at 31 March 2020 was £184.0 million reflecting normal working capital seasonality.

We are pleased to announce that the Group has entered into an agreement with its banking group to provide an additional £50 million revolving credit facility for a period of twelve months. This facility is in addition to the existing £300 million revolving credit facility made available under the RCF, which is committed through to November 2023, leaving the Group with £350 million of total revolving credit facilities for the next twelve months. We have also secured agreement from our banking group to temporarily waive certain requirements within the Group's RCF as a result of the impact of COVID-19 on the business and operations of the Group and to suspend the June 2020 quarterly leverage covenant test.

The Group has fully established (with all necessary programme documentation signed and dated 1 May 2020) a £100 million Euro-commercial paper programme ("ECP Programme"), initially without any public rating from a third party ratings agency, in response to the United Kingdom government's initiatives designed to help United Kingdom businesses with regard to the COVID-19 pandemic, details of which were published jointly by H.M. Treasury and the Bank of England on 23 March 2020.

Scenario analysis

Uncertainty around the scale, duration and impact of the COVID-19 pandemic on the markets in which Polypipe operates, namely the new house building and RMI market and the UK commercial and infrastructure markets, mean it is difficult at this time, to determine the impact on the performance of the Company and its subsidiaries (the "Group"), and the consequences for the Company's financial performance for the current financial year and beyond.

 

The Group has analysed a broad range of potential scenarios, primarily based on assumptions regarding the period of lockdown and the level of activity subsequently in both the Group's Residential and Commercial and Infrastructure divisions. However, this scenario analysis does not constitute financial guidance and no assurance can be given that any particular assumptions will prove correct or modelled scenarios will result.

 

This scenario analysis has focused on two key scenarios, which are summarised as follows:

an operating case where (i) trading in April to June 2020 continues to operate at approximately 70% below FY19 levels; (ii) a phased recovery in trading in July to September 2020; and (iii) trading through September to December 2020 and throughout FY21 in the Residential division and Commercial & Infrastructure divisions at levels of 15% and 10% respectively, below that achieved in FY19 (the "Operating Scenario"); and

a more prudent scenario where (i) trading in April to June 2020 continues to operate at approximately 70% below FY19 levels; (ii) a phased recovery in trading in July to September 2020; and (iii) trading through September to December 2020 and throughout FY21 in the Residential division and Commercial & Infrastructure divisions at levels of 25% and 20% respectively, below that achieved in FY19 (the "Prudent Scenario").

 

Although the Group entered this period of uncertainty with a strong balance sheet and good liquidity, the Group has needed to secure agreement from its banking group to temporarily waive certain requirements within the Group's RCF as a result of the impact of COVID-19 on the business and operations of the Group and to suspend the June 2020 quarterly leverage covenant test.

 

Polypipe has a strong track record of investment in new product development to drive growth and margin expansion. In recent years, Polypipe has invested between £20 million to £25 million per annum in innovative and exciting product and system launches. This investment is key to enhancing Polypipe's position as a leading provider of sustainable water and climate management solutions for the built environment and developing its 'one stop shop' offering for customers in the UK.

Rather than having to significantly curtail investment in new product development and capital expenditure and implement further cost reduction measures, all of which may damage the Company's long term operational capacity and competitive position, the Board has concluded that it is prudent to now raise equity.

Proposed equity placing

As a result, the Company has separately announced its intention to conduct a non-pre-emptive placing of new ordinary shares of the Company to raise total gross proceeds of approximately £120 million. The Chairman, Chief Executive Officer, Chief Financial Officer and some Non-Executive Directors intend to participate in the Placing.

The net proceeds from the Placing will be used to strengthen Polypipe's balance sheet and reduce overall debt. In the Prudent Scenario leverage will be reduced to 2.5x EBITDA (LTM) at the peak point in financial year 2021 creating an appropriate balance sheet structure while ensuring that the Group does not breach covenants in the financial years 2020 and 2021 or require further waivers that may or may not be forthcoming. In addition, the Placing, if completed would:

·      prevent investment being constrained and business decisions influenced by a focus on leverage and covenant management for the next 12 to 24 months and therefore managing the business in a manner that may cause detriment to Polypipe's long-term prospects;

·      enhance operating strength and enable continuation of organic investment in exciting new products & systems; and

·      provide stability and strength to increase competitive positioning and accelerate growth post COVID-19.

If the Placing were not to proceed, in the Prudent Scenario, peak net debt would be over 6x EBITDA (LTM) compared to a covenant of 3.0x EBITDA (LTM), and the Company would breach each of its quarterly covenants out to June 2021.

Board remuneration

As set out above, the Board has agreed to reduce base salaries for Executive Directors and base fees for Non-Executive Directors by 20% from 1 April 2020 until further notice. Furthermore, the grant of awards under the Polypipe Group plc Long Term Incentive Plan have been deferred and will be reconsidered by the Remuneration Committee in due course.

 

Enquiries:

 

Polypipe

Martin Payne, Chief Executive Officer

Paul James, Chief Financial Officer

 

+44 (0) 1709 770 000

Brunswick

Nina Coad / Charles Pretzlik

 

+44 (0) 20 7404 5959

     

 

Notes to Editors:

Polypipe Group plc ("Polypipe", the "Company" or the "Group"), a leading provider of sustainable water and climate management solutions for the built environment is the largest manufacturer in the UK, and among the ten largest manufacturers in Europe, of plastic piping systems for the residential, commercial, civils and infrastructure sectors by revenue.  It is also a leading designer and manufacturer of energy efficient ventilation systems in the UK.

The Group operates from 19 facilities in total, and with over 20,000 product lines, manufactures the UK's widest range of plastic piping systems for heating, plumbing, drainage and ventilation. The Group primarily targets the UK and European building and construction markets with a presence in Italy, the Netherlands, Ireland and the Middle East and sales to specific niches in the rest of the world.

 

Cautionary Statement

This Trading Update (the "Report") has been prepared in accordance with the Disclosure Guidance and Transparency Rules of the UK Financial Conduct Authority and is not audited. No representation or warranty, express or implied, is or will be made in relation to the accuracy, fairness or completeness of the information or opinions contained in this Report. Statements in this Report reflect the knowledge and information available at the time of its preparation. Certain statements included or incorporated by reference within this Report may constitute "forward-looking statements" in respect of the Group's operations, performance, prospects and/or financial condition. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions and actual results or events may differ materially from those expressed or implied by those statements. Accordingly, no assurance can be given that any particular expectation will be met and reliance shall not be placed on any forward-looking statement. Additionally, forward-looking statements regarding past trends or activities shall not be taken as a representation that such trends or activities will continue in the future. The information contained in this Report is subject to change without notice and no responsibility or obligation is accepted to update or revise any forward-looking statement resulting from new information, future events or otherwise. Nothing in this Report shall be construed as a profit forecast. This Report does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase or subscribe for any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares of the Company or any invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000. Past performance cannot be relied upon as a guide to future performance. Liability arising from anything in this Report shall be governed by English Law, and neither the Company nor any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this Report or its contents or otherwise arising in connection with this Report. Nothing in this Report shall exclude any liability under applicable laws that cannot be excluded in accordance with such laws.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUNVARRUUVRUR